CAR T-Cell Therapy Roundup

Chicago—The field of chimeric antigen receptor (CAR) therapy has been heating up, with the recent approval of Novartis’ CAR T-cell therapy tisagenlecleucel (Kymriah) for patients with acute lymphoblastic leukemia (ALL). Other CAR T-cell constructs are being tested in various hematologic malignancies with highly positive—albeit preliminary—results. Several early reports were presented at the 2017 annual meeting of the American Society of Clinical Oncology